Kedudukan dalam Saham
#23205
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on... Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.
Harga Saham
$1.81
Disegerakkan terakhir: 2026-08-21
Perubahan (1 tahun)
-23.63%
Perdagangan Annovis Bio, Inc. (ANVS)
Harga ANVS dengan permodalan pasaran b
Modal pasaran bagi Annovis Bio, Inc.(ANVS)
Modal Pasaran: $77.00M
Sehingga August 2026, Annovis Bio, Inc. mempunyai modal pasaran sebanyak $77.00M. Ini menjadikan Annovis Bio, Inc. syarikat ke-23205th paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran Annovis Bio, Inc. dari 2020 hingga 2026
ANVS berbanding dengan 5 teratas yang paling popular stocks
| Harga ANVS |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.211T
|
+6,767,871.37%
|
|
|
|
|
$4.547T
|
+5,904,729.87%
|
|
|
|
|
$4.162T
|
+5,405,680.85%
|
|
|
|
|
$3.593T
|
+4,665,834.28%
|
|
|
|
|
$2.793T
|
+3,626,962.00%
|
